Pathalys Pharma Unveils Encouraging Findings from Phase 3 Trials of Upacicalcet at ASN Kidney Week 2026#United_States#Denver#ASN_Kidney_Week#Pathalys_Pharma#upacicalcet
Pathalys Pharma Unveils Encouraging Findings from Phase 3 Trials of Upacicalcet at ASN Kidney Week 2026
Pathalys Pharma presented promising data on Upacicalcet at ASN Kidney Week 2026, demonstrating its efficacy in treating SHPT in hemodialysis patients.
third-news.com
October 23, 2026 at 11:38 PM
Pathalys Pharma Unveils Encouraging Findings from Phase 3 Trials of Upacicalcet at ASN Kidney Week 2026#United_States#Denver#ASN_Kidney_Week#Pathalys_Pharma#upacicalcet
Pathalys Pharma's Pivotal Phase 3 Study Findings to be Highlighted at ASN Kidney Week 2026#United_States#Raleigh#ASN_Kidney_Week#Pathalys_Pharma#upacicalcet
Pathalys Pharma's Pivotal Phase 3 Study Findings to be Highlighted at ASN Kidney Week 2026
Pathalys Pharma will present critical data on upacicalcet from its Phase 3 program at the ASN Kidney Week 2026, focusing on advancing CKD treatments.
third-news.com
October 5, 2026 at 1:32 PM
Pathalys Pharma's Pivotal Phase 3 Study Findings to be Highlighted at ASN Kidney Week 2026#United_States#Raleigh#ASN_Kidney_Week#Pathalys_Pharma#upacicalcet